isoleucine has been researched along with imatinib mesylate in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 6 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fermeglia, M; Ferrone, M; Pricl, S; Tamborini, E | 1 |
| Tuma, RS | 1 |
| Albitar, M; Cortes, J; Giles, F; Kantarjian, H; Lee, TS; Potts, SJ | 1 |
| Beug, H; Cerny-Reiterer, S; Gish, GD; Grebien, F; Hantschel, O; Kaupe, I; Koide, A; Koide, S; Kovacic, B; Pawson, T; Superti-Furga, G; Valent, P; Wojcik, J; Wyrzucki, AM | 1 |
| Diwu, L; Dong, T; Huang, J; Huang, Q; Kuang, P; Liu, T; Lu, X; Meng, W; Wang, Y; Xiang, B; Yang, S; Ye, Y | 1 |
| Ding, K; Leng, F; Li, Y; Long, H; Lu, X; Luo, J; Pan, X; Ren, X; Shen, M; Tu, Z; Wen, D; Zhang, F; Zhang, Z | 1 |
| Beadling, C; Bertagnolli, MM; Corless, CL; Demetri, GD; Fletcher, JA; Heinrich, MC; Lee, JC; Mariño-Enríquez, A; Morgan, JA; Ravegnini, G; Serrano, C; Wang, Y | 1 |
| Digumarti, R; Gundeti, S; Kagita, S; Uppalapati, S | 1 |
| Chantepie, S; Damaj, G; Decamp, M; Henry, A; Hueso, T; Johnson-Ansah, H; Maitre, E; Mensi, S; Vilque, JP | 1 |
9 other study(ies) available for isoleucine and imatinib mesylate
| Article | Year |
|---|---|
T315I-mutated Bcr-Abl in chronic myeloid leukemia and imatinib: insights from a computational study.
Topics: Antineoplastic Agents; Benzamides; Computational Biology; Computer Simulation; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation, Missense; Piperazines; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyrimidines; Threonine | 2005 |
With targeted drugs, chronic myelogenous leukemia therapy may follow HIV's model.
Topics: Antineoplastic Agents; Antiretroviral Therapy, Highly Active; Benzamides; Dasatinib; Drug Administration Schedule; Drug Costs; Fusion Proteins, bcr-abl; HIV Infections; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mutation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Thiazoles; Threonine; United States | 2007 |
Molecular basis explanation for imatinib resistance of BCR-ABL due to T315I and P-loop mutations from molecular dynamics simulations.
Topics: Adenosine Triphosphate; Antineoplastic Agents; Benzamides; Computer Simulation; Crystallography; Drug Resistance, Neoplasm; Genes, abl; Glutamic Acid; Humans; Imatinib Mesylate; Isoleucine; Methionine; Models, Molecular; Molecular Biology; Mutation; Piperazines; Protein Kinase Inhibitors; Protein Structure, Secondary; Protein-Tyrosine Kinases; Pyrimidines; Static Electricity; Threonine | 2008 |
Targeting the SH2-kinase interface in Bcr-Abl inhibits leukemogenesis.
Topics: Amino Acid Sequence; Animals; Base Sequence; Benzamides; Cells, Cultured; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Mice; Models, Molecular; Molecular Sequence Data; Piperazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrimidines; Signal Transduction; src Homology Domains | 2011 |
A novel I293MP mutation within BCR-ABL kinase domain in a Ph-positive acute lymphoblastic leukemia patient presenting resistant to imatinib but sensitive to nilotinib.
Topics: Adult; Amino Acid Substitution; Antineoplastic Agents; Base Sequence; Benzamides; Codon, Nonsense; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Models, Molecular; Phosphotransferases; Piperazines; Protein Structure, Tertiary; Pyrimidines | 2012 |
Design, synthesis, and biological evaluation of 3-(1H-1,2,3-triazol-1-yl)benzamide derivatives as Potent Pan Bcr-Abl inhibitors including the threonine(315)→isoleucine(315) mutant.
Topics: Benzamides; Blotting, Western; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Drug Design; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Molecular; Molecular Structure; Mutation; Phosphorylation; Piperazines; Protein Kinase Inhibitors; Pyrimidines; Structure-Activity Relationship; Threonine | 2012 |
KRAS and KIT Gatekeeper Mutations Confer Polyclonal Primary Imatinib Resistance in GI Stromal Tumors: Relevance of Concomitant Phosphatidylinositol 3-Kinase/AKT Dysregulation.
Topics: Antineoplastic Agents; Arginine; Benzamides; Carcinoma; Drug Resistance, Neoplasm; Gastrointestinal Stromal Tumors; Glycine; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation; Phosphatidylinositol 3-Kinase; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-kit; Proto-Oncogene Proteins p21(ras); Pyrimidines; ras Proteins; Sequence Analysis, DNA; Signal Transduction; Stomach Neoplasms; Threonine; Time Factors; TOR Serine-Threonine Kinases | 2015 |
Correlation of C/EBPα expression with response and resistance to imatinib in chronic myeloid leukaemia.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; CCAAT-Enhancer-Binding Protein-alpha; Cell Differentiation; Drug Resistance, Neoplasm; Female; Fusion Proteins, bcr-abl; Humans; Imatinib Mesylate; Isoleucine; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Middle Aged; Mutation; Piperazines; Predictive Value of Tests; Prognosis; Pyrimidines; Threonine | 2015 |
Successful Imatinib therapy as a bridge to transplant in an atypical myeloproliferative neoplasm.
Topics: Amino Acid Substitution; Combined Modality Therapy; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Humans; Imatinib Mesylate; Isoleucine; Male; Middle Aged; Mutation, Missense; Myeloproliferative Disorders; Neoadjuvant Therapy; Receptors, Colony-Stimulating Factor; Threonine; Transplantation, Homologous; Treatment Outcome | 2019 |